Australia's REA sweetens takeover offer for Britain's Rightmove to $8.1 billion
Citigroup's China expansion held up by US regulators, Bloomberg News reports
Oil edges up following US rate cut move, geopolitical concerns
Asia stocks hold steady as more rate cuts loom
White Sox left to ponder the magnitude of their record-tying 120 losses
The Rams rally from a double-digit deficit to stun the 49ers 27-24 on a late field goal
Henry rushes for 151 yards, 2 TDs as Ravens hang on to beat Cowboys 28-25
(Reuters) -Johnson & Johnson said on Tuesday it would buy privately held V-Wave for up to $1.7 billion, the healthcare conglomerate's second deal this year aimed at boosting its presence in the market for heart disease devices.
J&J said it will pay $600 million upfront, with potential payments of up to $1.1 billion contingent on regulatory and commercial milestones.
The deal is the latest in a string of acquisitions by J&J as it looks to drive growth beyond 2025, when blockbuster psoriasis drug Stelara is expected to face biosimilar rivals.
In April, J&J said it would buy Shockwave Medical in a deal valued at $13.1 billion including debt. Other recent deals include its $1.25 billion acquisition of Numab's skin disorder drug, and its $850 million deal for Proteologix.
The V-Wave deal pushes J&J further into the high-growth market for heart failure devices, said RBC Capital Markets analyst Shagun Singh. With the device expected to treat a condition that affects 800,000 patients every year, it should represent a stable and meaningful market opportunity for J&J, Singh added.
V-Wave's device is implanted in the heart through a minimally invasive procedure to help reduce heart failure and other cardiovascular events. It is not yet cleared for use in the United States.
(Reporting by Manas Mishra and Unnamalai L in Bengaluru; Editing by Devika Syamnath)
